Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review
BackgroundEarly studies have revealed antagonistic effects associated with stacking chemotherapy (CT) and endocrine therapy (ET), thereby conventional wisdom does not advocate the simultaneous combination of these two treatment modalities. Limited clinical studies exist on the combined use of neoadj...
Main Authors: | Nengying Zhang, Chengmin Luo, Jiayang Li, Yuxiang Bao, Zhongliang Yan, Xiaoming Cheng, Taolang Li, Junyuan Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1362725/full |
Similar Items
-
Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
by: Javier A. Menendez, et al.
Published: (2020-10-01) -
Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023-04-01) -
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
by: Li Y, et al.
Published: (2020-06-01) -
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
by: Xue-Lian Chen, et al.
Published: (2016-04-01) -
Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
by: Fulvio Borella, et al.
Published: (2023-08-01)